Identification of biologically effective dose-volumetric parameters that predict radiation-induced hepatic toxicity in patients treated with helical tomotherapy for unresectable locally advanced hepatocellular carcinoma

Jin Ho Song, Seok Hyun Son, Chul Seung Kay, Hong Seok Jang

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

The purpose of this study is to identify dose-volumetric parameters that predict radiation-induced hepatic toxicity (RIHT) by analyzing the relationship between the biologically effective dose (BED) delivered to the normal liver and RIHT. The clinical and dosimetric data from 123 patients with unresectable hepatocellular carcinoma (HCC) treated with helical tomotherapy were analyzed. The median radiation dose was a 50 Gy in 4.5 Gy fractions (range, 30-60 Gy in 1.8-5.0 Gy fractions) to 95% of the planning target volume. RIHT was defined as a Child-Pugh score increase of at least 2 points within 3 months of helical tomotherapy completion. RIHT developed in 60 patients (48.7%). Multivariate logistic regression analysis showed that VBED20 (percentage of nontarget normal liver volume that received more than a BED of 20 Gy) was a significant parameter (P<0.001), and the cut-off value was 40.8% with a sensitivity and specificity of 0.833 and 0.698, respectively, according to the receiver operating characteristic curve (P<0.001). Maintaining a VBED20 below 40.8% will reduce the risk of RIHT, and the proposed normal liver tolerance curve could be a useful guideline when treating unresectable HCC patients with various radiotherapy dose schedules.

Original languageEnglish
Article numbere1904
JournalMedicine (United States)
Volume94
Issue number43
DOIs
StatePublished - 2015

Bibliographical note

Publisher Copyright:
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.

Fingerprint

Dive into the research topics of 'Identification of biologically effective dose-volumetric parameters that predict radiation-induced hepatic toxicity in patients treated with helical tomotherapy for unresectable locally advanced hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this